cemka > Publications > Infectiologie

Classer les publications sur l'année

  • Économie de la santĂ©

    Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection

    PECHEVIS M, KHOSHNOOD B, BUTEAU L, DURAND I, PIQUARD Y, LAFUMA A

    Vaccine ; 21: 3556-3564

  • SantĂ© Publique et EpidĂ©miologie

    Evaluation du programme oRchestra d’amĂ©lioration de la prise en charge globale des patients infectĂ©s par le VIH

    MASSIP P, BEZ J, ROUSSELLE-KOCH B, CUZIN L, DELPIERRE C, DETOURNAY B, VOINET C

    Gestions HospitaliĂšres ; 2002(420):722-727

  • Économie de la santĂ©

    Economic evaluation of vaccination programmes: a Consensus Statement Focusing on Viral Hepatitis

    BEUTELS P, EDMUNDS WJ, ANTONANZAS F, DE WIT GA, EVANS D, FEILDEN R, FENDRICK AM, GINSBERG GM, GLICK HA, MAST E, PECHEVIS M, VAN DOORSLAER E, BA, VAN HOUT

    Pharmacoeconomics ; 20(1):1-7

  • Économie de la santĂ©

    Cost of Care for Inpatients with Community -Acquired Intra-Abdominal Infections

    CATTAN P, YIN DD, SARFATI E, LYU R, DE ZELICOURT M, FAGNANI F

    Eur J Clin Microbiol Infect Dis ; 21: 787-793

  • Économie de la santĂ©

    Cost and effectiveness of ciprofloxacin + hydrocortisone versus neomycin + polymyxin B + hydrocortisone in France for the treatment of acute otitis externa

    LAFUMA A, FAGNANI F, BERDEAUX G

    Journal of Medical Economics ; 2002;5:11-23

  • Pharmaco-EpidĂ©miologie

    HĂ©pavir, premiĂšre Ă©tude observationnelle d’une cohorte de malades traitĂ©s par interfĂ©ron alpha-2a en monothĂ©rapie

    ROUDOT-THORAVAL F, ABERGEL A, ALLAERT F, BOURLIERE M, DESMORAT H, FAGNANI F, FONTANGES T, HANANA A, POL S, ZARSKI JP, ROUSSEAUX C, GANDOSSI C, ABELSOUR L, DOLE S, DANTIN S, EBERLE F, SAINT-MARC-GIRARDIN MF, Le Groupe d’Etude pour HEpavir

    Gastroenterol Clin Biol ; 2001 (25) : 1061-1066

  • Économie de la santĂ©

    Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era

    CACOUB P, VAUTIER M, DESBOIS AC, LAFUMA A, SAADOUN D

    Liver International ; 2017:37(12):1805-1813

  • Pharmaco-EpidĂ©miologie

    An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

    M LLIBRE J, RAFFI F, MOYLE G, BEHRENS G, BOUEE S, REILLY G, BORG P, PIONTKOWSKY D, ROGATTO F.

    PLoS One ; 2016;102(2):143-148

  • Économie de la santĂ©

    Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals

    LE MONNIER A, DUBURCQ A, ZAHAR JR, CORVEC S, GUILLARD T, CATTOIR V, WOERTHER PL, FIHMAN V, LALANDE V, JACQUIER H, MIZRAHI A, FARFOUR E, MORAND P, MARCADÉ G, COULOMB S, TORRETON E, FAGNANI F, BARBUT F, GMC STUDY GROUP

    J Hosp Infect ; 2015;91:117-122

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database

    RAFFI F, YAZDANPANAH Y, FAGNANI F, LAURENDEAU C, LAFUMA A, GOURMELEN J

    J Antimicrob Chemother ; 2015;70:2121-2128

  • Économie de la santĂ©

    Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals

    LE MONNIER A, DUBURCQ A, ZAHAR JR, CORVEC S, GUILLARD T, CATTOIR V, WOERTHER PL, FIHMAN V, LALANDE V, JACQUIER H, MIZRAHI A, FARFOUR E, MORAND P, MARCADÉ G, COULOMB S, TORRETON E, FAGNANI F, BARBUT F, GMC STUDY GROUP

    J Hosp Infect ; 2015;91:117-22

  • Économie de la santĂ©

    A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical

    DEMARTEAU N, DETOURNAY B, TEHARD B, EL HASNAOUI A, STANDAERT B

    Int J Public Health ; 2011;56(2):153-62

  • Économie de la santĂ©

    The cost of managing HIV infection in highly treatment-experienced, HIV-Infected adults in France

    COLIN X, LAFUMA A, COSTAGLIOLA D, LANG JM, GUILLON P

    Pharmacoeconomics ; 2010;28(S1):59-68

  • SantĂ© Publique et EpidĂ©miologie

    PrĂ©vac B: prĂ©vention de l’hĂ©patite B dans les populations migrantes originaires de zones de forte endĂ©mie, Afrique subsaharienne et Asie

    AUBERT JP, CATRICE M, BOUEE S, DI PUMPO A, SANTANA P, GERVAIS A, WAJSBROT A, GELLY J, NOUGAIREDE M

    Revue du Praticien (supplément) ; 2010;60:13-20

  • Économie de la santĂ©

    Modelling the budget impact of Darunavir in the treatment of highly treatment-experienced, HIV-Infected adults in France

    COLIN X, LAFUMA A, COSTAGLIOLA D, SMETS E, MAUSKOPF J, GUILLON P

    Pharmacoeconomics ; 2010;28(S1):183-197